Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This phase 1 study compared the pharmacokinetics of a single intravenous dose of SHR-8068 injection with ipilimumab (YERVOY®) in healthy Chinese men. Safety and immunogenicity were also evaluated.
Full description
The study comprised an open-label pilot stage and a double-blind formal stage. In the pilot stage, 12 healthy Chinese men were randomized in parallel to receive a single 0.3 mg/kg intravenous infusion of SHR-8068 (n=6) or ipilimumab (n=6). The pilot evaluated safety, pharmacokinetic characteristics and variability, and immunogenicity, and informed optimization of pharmacokinetic and immunogenicity sampling for the formal stage.
In the formal stage, 112 healthy Chinese men were randomized in a 1:1 ratio, under double-blind conditions, to receive a single 0.3 mg/kg intravenous infusion of SHR-8068 (n=56) or ipilimumab (n=56) in a single-period, parallel design. The primary pharmacokinetic parameters were maximum serum concentration (Cmax) and area under the serum concentration-time curve from time zero extrapolated to infinity (AUC0-inf). Other pharmacokinetic parameters, safety, and immunogenicity were also evaluated. Formal-stage pharmacokinetic equivalence was assessed using the 90% confidence intervals for the geometric mean ratios of Cmax and AUC0-inf, with prespecified limits of 80.00% to 125.00%.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
124 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal